SHR-1905 treatment for moderate-to-severe atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial gives adults with moderate-to-severe atopic dermatitis injections of SHR-1905 or a blank preparation and monitors response and side effects. Participants must be 18–75 years old, able to consent, and meet inclusion/exclusion criteria. The primary focus is on clinical skin outcomes and safety measured during the treatment period at a single site in Guangzhou, China. Investigators will compare symptom improvement and adverse events between the SHR-1905 and blank-preparation groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study.
2. At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female.
3. Have atopic dermatitis at screening.

Exclusion Criteria:

1. Hypersensitivity to the study drug or any ingredient in the study drug.
2. Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD).
3. Has malignancy or has a history of malignancy.
4. Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial.
5. Females who are pregnant or lactating.

Where it's running

• Dermatology Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Ran Li
• Email: ran.li@hengrui.com
• Phone: +86-0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A Phase 3 test of Rezpegaldesleukin (NKTR-358) for moderate-to-severe atopic dermatitis in patients 12 years and older

  This Phase 3 study tests whether Rezpegaldesleukin helps people aged 12 and up with moderate-to-severe atopic dermatitis compared to placebo.

  Recruiting at 13 sites Phase 3 Nektar Therapeutics · Birmingham, Alabama and 12 other locations · NCT07711418

• Rezpegaldesleukin for moderate-to-severe atopic dermatitis in people 12 and older

  This study tests whether Rezpegaldesleukin helps people aged 12 and up with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting at 20 sites Phase 3 Nektar Therapeutics · Phoenix, Arizona and 19 other locations · NCT07690371

• Nemolizumab for infants with moderate-to-severe atopic dermatitis

  This study tests whether nemolizumab can be safely given to infants aged 6 to under 24 months to help manage moderate-to-severe eczema when topical treatments alone aren’t enough.

  Recruiting Phase 2 Galderma R&D · San Antonio, Texas · NCT07660835

• SYX-5219 in healthy adults and adults with moderate-to-severe atopic dermatitis

  This trial will test oral SYX-5219 in healthy adults and in adults with moderate-to-severe atopic dermatitis to see if it is safe, well tolerated, and how the drug is processed in the body.

  Recruiting at 12 sites Phase 1 Sitryx Therapeutics Ltd · Arkansas City, Arkansas and 13 other locations · NCT07558668

• Oral LW402 for moderate-to-severe atopic dermatitis

  This phase 3 study tests whether oral LW402 tablets can help adults with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting Phase 3 Shanghai Longwood Biopharmaceuticals Co., Ltd. · Beijing · NCT07370909

• TRB-061 injections for healthy adults and people with moderate-to-severe atopic dermatitis

  This trial will test subcutaneous TRB-061 injections in healthy adults and adults with moderate-to-severe atopic dermatitis to check safety, dosing, and how the drug acts in the body.

  Recruiting at 18 sites Phase 1 TRex Bio, Inc. · Deakin, Australian Capital Territory and 18 other locations · NCT06934252

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.